Ryvu Therapeutics Presents Data on RVU120 at the San Antonio Breast Cancer Symposium 2023

Read More

Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

Read More

Ryvu Therapeutics provides an update on the progress of RVU120 Phase I studies in patients with solid tumors and AML/HR-MDS, and presents the updated development plan for RVU120

Read More

Expansion of Clinical Development of RVU120 in Low-Risk Myelodysplastic Syndromes (LR-MDS)

Read More

Ryvu Therapeutics Presents Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Read More

Ryvu Therapeutics to Present Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Read More

Ryvu Therapeutics’ Global Licensee Menarini to Expand Development of MEN1703 (SEL24) with a New Study in Advanced Diffuse Large B-Cell Lymphoma (DLBCL)

Read More

Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provides Corporate Update

Read More

Ryvu Therapeutics to Participate in the 31st Congress of the Polish Society of Hematology and Transfusion Medicine

Read More

Ryvu Therapeutics Announces Signing Two Agreements with Fortrea to Operationally Execute Phase II Clinical Trials of RVU120 in Hematology

Read More